Ultima-CJC No DAC contains CJC-1295 No DAC, commonly known as Modified GRF 1-29. It is a short-acting GHRH analogue designed to stimulate the body’s own growth hormone release. Its shorter activity profile makes it especially popular in fitness-focused peptide protocols centered around recovery, lean muscle development, body composition, and growth hormone support.

How it works

CJC-1295 No DAC binds to growth hormone-releasing hormone (GHRH) receptors on pituitary cells, stimulating the release of growth hormone. This activates the GH–IGF-1 pathway, which is involved in protein metabolism, tissue maintenance, recovery, and body composition.

Because it does not contain the Drug Affinity Complex (DAC), it has a shorter-acting profile than CJC-1295 DAC. This allows it to produce shorter, more pulse-like growth hormone stimulation.

Proper Use and Dosage

The listed product contains 5 mg (5,000 mcg) per vial.

CJC-1295 No DAC is generally used in small, repeated subcutaneous administrations because of its short activity profile. Commonly referenced peptide protocols use approximately 100–300 mcg per administration, with administration frequency adjusted according to the specific protocol.

For example, at 100 mcg per administration, a 5 mg vial contains approximately 50 administrations. At 200 mcg, it provides approximately 25 administrations, while 300 mcg provides approximately 16 administrations.

CJC-1295 No DAC is also frequently combined with growth-hormone secretagogues such as Ipamorelin or GHRP-6, allowing GHRH and ghrelin-receptor pathways to work together to stimulate GH release.

Benefits

Ultima-CJC No DAC is particularly suited to fitness-focused goals involving growth hormone stimulation, recovery, physique development, and body composition.

Key benefits include:

• Supports natural growth hormone release
• Promotes GH–IGF-1 pathway activity
• Supports recovery following intense training
• Complements lean-muscle and physique-focused goals
• Supports research into protein metabolism and tissue maintenance
• Provides a short-acting GHRH analogue
• Produces a pulse-oriented GH stimulation profile
• Can complement Ipamorelin and GHRP-6
• Provides a concentrated 5 mg presentation for repeated-use protocols

Its short-acting profile makes CJC-1295 No DAC especially attractive for protocols designed around controlled, transient growth hormone stimulation rather than the prolonged activity associated with the DAC version.

Side Effects

Possible effects associated with growth-hormone stimulation include headache, flushing, dizziness, fatigue, water retention, joint discomfort, and injection-site reactions. Some individuals may also notice temporary changes in appetite or sleep.